ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 331 for:    SERTRALINE

Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety (ToSCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02347033
Recruitment Status : Terminated (Difficulties with recruitment during the internal pilot phase)
First Posted : January 27, 2015
Last Update Posted : July 11, 2016
Sponsor:
Collaborators:
NHS Health Technology Assessment Programme
National Institute for Health Research, United Kingdom
Information provided by (Responsible Party):
University College, London

Brief Summary:

Generalised Anxiety Disorder (GAD) is common, causes unpleasant symptoms and impairs people's functioning. It is often chronic and may be accompanied by depression and other anxiety disorders. It is not currently clear whether medication or psychological therapy provides better long term outcomes for those not responding to simpler low intensity treatments so we propose to compare the clinical effectiveness of a pharmacological treatment (the drug Sertraline) with a Cognitive Behavioural Therapy (CBT) intervention.

Our hypothesis is that in people with GAD who have not responded to low intensity psychological interventions, CBT will lead to a greater improvement in their GAD symptoms as measured using the GAD-7 scale at 12 month follow-up than Sertraline.


Condition or disease Intervention/treatment Phase
Generalised Anxiety Disorder Drug: Sertraline Behavioral: Cognitive Behavioural Therapy Phase 4

Detailed Description:

The investigators propose to undertake a randomised controlled trial (RCT) to compare the clinical effectiveness in terms of symptoms and function of a pharmacological treatment (the SSRI Sertraline) prescribed at therapeutic doses, with a manualised psychological intervention (Cognitive Behavioural Therapy, CBT) delivered by trained psychological therapists to patients with persistent generalised anxiety disorder (GAD) which has not improved with low intensity psychological interventions as defined by NICE (the National Institute for Clinical Effectiveness).

The investigators will recruit people via the Increasing Access to Psychological Therapies (IAPT) service from up to 15 sites in England. People still scoring highly on an anxiety measure (GAD-7) despite having received a low intensity psychological intervention will be given a brief flyer about the trial. Names of those interested in taking part who have given written consent to having their details released will be passed to the research team and the IAPT staff will also let the research team know the name of the participant's general practice, with their permission.

The research team will then contact potential participants offering them an appointment for an interview/assessment to discuss the study, sending them a patient information sheet to reach them at least 48 hours beforehand. The study information will explain that the medication being evaluated, Sertraline, although not currently licensed for GAD was recommended by NICE on the basis of its effectiveness in clinical trials and that the study team will be available to clarify any issues arising from this.

At the baseline assessment patients will be asked to give informed consent by a member of the research team and both medical suitability (as confirmed by fax/secure email from the GP) and the meeting of other inclusion/exclusion criteria will be checked. Upon confirmation of eligibility, baseline assessments will be carried out by a member of the research team and consenting patients randomised to receive either the medication or CBT. The Chief Investigator or other medically qualified persons within the research team will review all eligibility information and confirm that the patient is eligible.

Eligible participants will be randomised via an independent web-based computerised system to one of two interventions. The research team will provide the relevant contact details/instructions to patients in order to initiate treatment. The trial interventions consist of: (a) The medication sertraline prescribed by their GP according to a trial protocol matching current clinical recommendations and within a dosage between 25 and 150mg daily. We will ask GPs to review patients regularly (at least 6 times in 12 months) and patients to take the medication for a year unless they have significant adverse effects. Side-effects will be regularly monitored. (b) The other intervention is CBT delivered by high intensity therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed for use in GAD and will be trained in its delivery. The primary outcome will be the GAD-7 score measured at 12 months. Participants will also be asked to complete this outcome measure by postal questionnaire at 3, 6 and 9 months, as well as a range of secondary outcomes.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RCT of Sertraline Versus Cognitive Behavioural Therapy for Anxiety Symptoms in People With Generalised Anxiety Disorder Who Have Failed to Respond to Low Intensity Psychological Interventions as Defined by the NICE GAD Guidelines
Study Start Date : August 2014
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Active Comparator: Sertraline
The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
Drug: Sertraline

Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.

We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks.

Other Name: SSRI

Active Comparator: Cognitive Behavioural Therapy (CBT)
The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
Behavioral: Cognitive Behavioural Therapy

CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.

Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent.

Other Name: CBT




Primary Outcome Measures :
  1. GAD-7 [ Time Frame: GAD-7 score at 12 months ]
    A 7 item self-complete questionnaire with very good sensitivity (89%) and specificity (82%) for Generalised Anxiety Disorder (GAD).


Secondary Outcome Measures :
  1. GAD-7 [ Time Frame: GAD-7 score at 3 months ]
    A 7 item self-complete questionnaire with very good sensitivity (89%) and specificity (82%) for Generalised Anxiety Disorder (GAD).

  2. GAD-7 [ Time Frame: GAD-7 score at 6 months ]
    A 7 item self-complete questionnaire with very good sensitivity (89%) and specificity (82%) for Generalised Anxiety Disorder (GAD).

  3. GAD-7 [ Time Frame: GAD-7 score at 9 months ]
    A 7 item self-complete questionnaire with very good sensitivity (89%) and specificity (82%) for Generalised Anxiety Disorder (GAD).

  4. HAM-A [ Time Frame: HAM-A score at 12 months ]
    This is a 14 item observer rated anxiety scale which has been widely used, particularly in pharmacological studies widely used, particularly in pharmacological studies

  5. Patient Health Questionnaire (PHQ-9) [ Time Frame: PHQ-9 score at 3 months ]
    This is a 9 item self-rate scale widely used to monitor the severity of depression.

  6. Patient Health Questionnaire (PHQ-9) [ Time Frame: PHQ-9 score at 6 months ]
    This is a 9 item self-rate scale widely used to monitor the severity of depression.

  7. Patient Health Questionnaire (PHQ-9) [ Time Frame: PHQ-9 score at 9 months ]
    This is a 9 item self-rate scale widely used to monitor the severity of depression.

  8. Patient Health Questionnaire (PHQ-9) [ Time Frame: PHQ-9 score at 12 months ]
    This is a 9 item self-rate scale widely used to monitor the severity of depression.

  9. Work and Social Activity Scale (WASAS) [ Time Frame: WASAS score at 12 months ]
    This is a 5 item self-complete questionnaire which we will use to assess participants' difficulties with physical and social functioning

  10. Euroquol-5 item-3 level (EQ-5D-3L) [ Time Frame: Utility score at 3 months ]
    5 item, 3 level, self-completed measure of preference based generic health related quality of life. Utility scores calculated at each time point

  11. Euroquol-5 item-3 level (EQ-5D-3L) [ Time Frame: Utility score at 6 months ]
    5 item, 3 level, self-completed measure of preference based generic health related quality of life. Utility scores calculated at each time point scores for Quality Adjusted Life Years

  12. Euroquol-5 item-3 level (EQ-5D-3L) [ Time Frame: Utility score at 9 months ]
    5 item, 3 level, self-completed measure of preference based generic health related quality of life. Utility scores calculated at each time point scores for Quality Adjusted Life Years

  13. Euroquol-5 item-3 level (EQ-5D-3L) [ Time Frame: Utility score at 12 months ]
    5 item, 3 level, self-completed measure of preference based generic health related quality of life. Utility scores calculated at each time point scores for Quality Adjusted Life Years

  14. Employment and Social Care Questionnaire (ESC) [ Time Frame: ESC score at 6 months ]
    Relevant data on services used and productivity losses will be collected using this modified version of the Client Service Receipt Inventory

  15. Employment and Social Care Questionnaire (ESC) [ Time Frame: ESC score at 12 months ]
    Relevant data on services used and productivity losses will be collected using this modified version of the Client Service Receipt Inventory

  16. (CSQ) Client Satisfaction Questionnaire [ Time Frame: CSQ score at 3 months ]
    We are going to use the Client Satisfaction Questionnaire, a brief 8-item self-complete questionnaire as our treatment acceptability measure.

  17. (CSQ) Client Satisfaction Questionnaire [ Time Frame: CSQ score at 12 months ]
    We are going to use the Client Satisfaction Questionnaire, a brief 8-item self-complete questionnaire as our treatment acceptability measure.

  18. Patient preference rating scale [ Time Frame: Patient preference rating scale score at 12 months ]
    We are using a simple 4 item Likert scale used by our team in other studies


Other Outcome Measures:
  1. Health service outcome - General practitioner (GP) contacts [ Time Frame: GP contacts at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include the number of GP contacts.

  2. Health service outcome - Practice nurse contacts [ Time Frame: Practice nurse contacts at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include the number of practice nurse contacts.

  3. Health service outcome - referrals to secondary care medical services [ Time Frame: Referrals to secondary care medical services at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include the number of referrals to secondary care medical services

  4. Health service outcome - referrals to psychological therapy services [ Time Frame: Referrals to psychological therapy services at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include referrals to psychological therapy services.

  5. Health service outcome - referrals to psychiatric services [ Time Frame: Referrals to psychiatric services at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include the number of referrals to psychiatric services.

  6. Health service outcome - prescriptions for psychotropic medication [ Time Frame: Prescriptions for psychotropic medication at 12 months ]
    We will collect relevant health service use data from both intervention arms at 12 months for the previous 12 months. This will include the number of prescriptions for psychotropic medication



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 or above
  • Positive score of 10+ on GAD-7
  • Primary diagnosis of GAD as diagnosed on MINI
  • Failure to respond to NICE defined low intensity psychological interventions

Exclusion Criteria:

  • Inability to complete questionnaires due to insufficient English or cognitive impairment;
  • Current major depression
  • Other comorbid anxiety disorder(s) of more severity or distress to the participant than their GAD;
  • Significant dependence on alcohol or illicit drugs;
  • Comorbid psychotic disorder, bipolar disorder;
  • Treatment with antidepressants in past 8 weeks or any high intensity psychological therapy within past 6 months;
  • Currently on contraindicated medication: monoamine oxidase Inhibitors within the past 14 days or pimozide;
  • Patients with poorly controlled epilepsy;
  • Known allergies to the Investigational Medicinal Product (IMP) or excipients;
  • Concurrent enrolment in another Investigational Medicinal Product trial;
  • Severe hepatic impairment;
  • Women who are currently pregnant or planning pregnancy or lactating
  • Patient on anti-coagulants
  • History of bleeding disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02347033


Locations
United Kingdom
Camden & Islington (with Kingston)
London, United Kingdom, WC1X 2DN
Sponsors and Collaborators
University College, London
NHS Health Technology Assessment Programme
National Institute for Health Research, United Kingdom
Investigators
Principal Investigator: Marta Buszewicz University College, London

Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT02347033     History of Changes
Other Study ID Numbers: 14/0249
First Posted: January 27, 2015    Key Record Dates
Last Update Posted: July 11, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: To be discussed and decided by the Data Monitoring Committee

Keywords provided by University College, London:
Sertraline
Selective Serotonin Reuptake Inhibitor (SSRI)
Cognitive Behavioural Therapy (CBT)
Increasing Access to Psychological Therapies (IAPT)

Additional relevant MeSH terms:
Sertraline
Anxiety Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Antidepressive Agents
Psychotropic Drugs
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs